Cargando…

Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline

BACKGROUND & OBJECTIVES: Hyperprolactinaemia affects testicular functions by influencing hypothalamo-pituitary-testicular (HPT) axis at various levels. Available literature on the level of defect, time course of improvement of gonadal functions and its relation with decline in prolactin levels i...

Descripción completa

Detalles Bibliográficos
Autores principales: Walia, Rama, Bhansali, Anil, Dutta, Pinaki, Khandelwal, Niranjan, Sialy, Ravinder, Bhadada, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193712/
https://www.ncbi.nlm.nih.gov/pubmed/21985814
_version_ 1782213869677051904
author Walia, Rama
Bhansali, Anil
Dutta, Pinaki
Khandelwal, Niranjan
Sialy, Ravinder
Bhadada, Sanjay
author_facet Walia, Rama
Bhansali, Anil
Dutta, Pinaki
Khandelwal, Niranjan
Sialy, Ravinder
Bhadada, Sanjay
author_sort Walia, Rama
collection PubMed
description BACKGROUND & OBJECTIVES: Hyperprolactinaemia affects testicular functions by influencing hypothalamo-pituitary-testicular (HPT) axis at various levels. Available literature on the level of defect, time course of improvement of gonadal functions and its relation with decline in prolactin levels is scanty. We carried out this study to evaluate the HPT axis in patients with macroprolactinomas, before and six months after cabergoline therapy. METHODS: Fifteen men with macroprolactinomas underwent gonadotropin and testosterone response to their respective stimuli before and after six months of cabergoline therapy. RESULTS: Serum prolactin levels decreased after six months of therapy. Pretreatment, mean lutenizing and follicle stimulating hormones (LH and FSH) levels were 2.0 ± 0.4 and 1.4 ± 0.2 IU/l, respectively. However, LH and FSH responses to GnRH were preserved in majority of the patients and LH peaked to 12.1 ± 2.3 IU/l (P<0.01), while FSH to 2.9 ± 0.4 IU/l suggesting the influence of hyperprolactinaemia at the level of hypothalamus with preserved gonadotrope reserve. After cabergoline therapy, there was an increase in basal as well as stimulated LH and FSH levels, though these were not statistically significant when compared to respective pretherapy levels. Basal testosterone (T) levels significantly improved after therapy, but peak T response to hCG was similar at both pre- and post treatment. A significant correlation was observed between peak LH and peak T at baseline (r=0.53, P<0.01) and it further strengthened after therapy (r=0.70, P<0.01). After cabergoline therapy, there was significant improvement in seminal volume, sperm count and motility and sperm count correlated with peak FSH response (r=0.53, P<0.05). INTERPRETATION & CONCLUSIONS: Hyperprolactinaemia affects testicular functions probably by influencing at the level of hypothalamus resulting in subnormal basal secretion of gonadotropins required for optimal testicular functions.
format Online
Article
Text
id pubmed-3193712
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31937122011-10-21 Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline Walia, Rama Bhansali, Anil Dutta, Pinaki Khandelwal, Niranjan Sialy, Ravinder Bhadada, Sanjay Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Hyperprolactinaemia affects testicular functions by influencing hypothalamo-pituitary-testicular (HPT) axis at various levels. Available literature on the level of defect, time course of improvement of gonadal functions and its relation with decline in prolactin levels is scanty. We carried out this study to evaluate the HPT axis in patients with macroprolactinomas, before and six months after cabergoline therapy. METHODS: Fifteen men with macroprolactinomas underwent gonadotropin and testosterone response to their respective stimuli before and after six months of cabergoline therapy. RESULTS: Serum prolactin levels decreased after six months of therapy. Pretreatment, mean lutenizing and follicle stimulating hormones (LH and FSH) levels were 2.0 ± 0.4 and 1.4 ± 0.2 IU/l, respectively. However, LH and FSH responses to GnRH were preserved in majority of the patients and LH peaked to 12.1 ± 2.3 IU/l (P<0.01), while FSH to 2.9 ± 0.4 IU/l suggesting the influence of hyperprolactinaemia at the level of hypothalamus with preserved gonadotrope reserve. After cabergoline therapy, there was an increase in basal as well as stimulated LH and FSH levels, though these were not statistically significant when compared to respective pretherapy levels. Basal testosterone (T) levels significantly improved after therapy, but peak T response to hCG was similar at both pre- and post treatment. A significant correlation was observed between peak LH and peak T at baseline (r=0.53, P<0.01) and it further strengthened after therapy (r=0.70, P<0.01). After cabergoline therapy, there was significant improvement in seminal volume, sperm count and motility and sperm count correlated with peak FSH response (r=0.53, P<0.05). INTERPRETATION & CONCLUSIONS: Hyperprolactinaemia affects testicular functions probably by influencing at the level of hypothalamus resulting in subnormal basal secretion of gonadotropins required for optimal testicular functions. Medknow Publications 2011-09 /pmc/articles/PMC3193712/ /pubmed/21985814 Text en Copyright: © The Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Walia, Rama
Bhansali, Anil
Dutta, Pinaki
Khandelwal, Niranjan
Sialy, Ravinder
Bhadada, Sanjay
Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
title Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
title_full Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
title_fullStr Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
title_full_unstemmed Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
title_short Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
title_sort recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193712/
https://www.ncbi.nlm.nih.gov/pubmed/21985814
work_keys_str_mv AT waliarama recoverypatternofhypothalamopituitarytesticularaxisinpatientswithmacroprolactinomasaftertreatmentwithcabergoline
AT bhansalianil recoverypatternofhypothalamopituitarytesticularaxisinpatientswithmacroprolactinomasaftertreatmentwithcabergoline
AT duttapinaki recoverypatternofhypothalamopituitarytesticularaxisinpatientswithmacroprolactinomasaftertreatmentwithcabergoline
AT khandelwalniranjan recoverypatternofhypothalamopituitarytesticularaxisinpatientswithmacroprolactinomasaftertreatmentwithcabergoline
AT sialyravinder recoverypatternofhypothalamopituitarytesticularaxisinpatientswithmacroprolactinomasaftertreatmentwithcabergoline
AT bhadadasanjay recoverypatternofhypothalamopituitarytesticularaxisinpatientswithmacroprolactinomasaftertreatmentwithcabergoline